The authors state their own conclusion this way: valproate exposure was associated with an increased risk of polycystic ovary syndrome in women with bipolar disorder or epilepsy, with the strongest associations observed for current cumulative exposure and additional risk apparent at high cumulative dosages, while overall cumulative exposure showed a less clear dose-response pattern.

The authors conclude that "Data suggest a favorable benefit-risk profile for AOM 400 versus placebo as a long-term maintenance treatment for BP-I", and all four of the paper's benefit-harm ratios are built on who stopped attending, while the akathisia in 21.2% of patients and the weight gain in 23.5% are printed one table earlier and never enter them.

The outcome here is an admission recorded by a national register rather than anything a patient or a clinician rated, and the deaths of 4,565 people in the cohort were used to end observation rather than counted as an outcome.

The outcome here is a death certificate rather than a craving score, and it shows that a patient admitted to a narcology ward carries three times the all-cause mortality of a low-risk drinker, with a modelled ninefold for external causes that rests on 20 deaths and a very wide confidence interval, from 2.63 to 33.3.

The lesion map earns its keep at the dementia end of the spectrum and goes quiet exactly where an early marker would be worth having.

A cognitive score moved by three and a half points while daily function only held level and no change in quality of life was reported, and that gap is not a pharmacological problem.

The zero cell in this table is not a discovery about complex PTSD; it is a consequence of scoring the complex PTSD subscale from the PTSD items plus two.

In this post hoc analysis baseline dissociation predicted a smaller gain, not a failed treatment: nobody in the trial reliably worsened, and the heaviest dissociators whose symptoms shifted early gained the most.

The sentence the authors placed in their conclusion and not in their abstract: lithium treatment should neither be withheld nor continued reflexively solely on the basis of renal concerns, and what replaces the reflex is an individualized, trajectory-based assessment that balances substantial therapeutic benefit against renal risk, preserving lithium's role as a first-line treatment while safeguarding long-term patient health.

The trial is called Screen, Treat and Retain, and retention in methadone treatment is neither among the outcomes it reports nor among the sixteen it registered: what it reports is methamphetamine-negative urine, twice a week, for 25 weeks.

This trial has no objective sleep outcome at all: the registered actigraphy was usable in 22.3% of dyads at 8 months, and every reported number came from the unmasked family carer.

The registered primary outcome had two halves, and the physiological half was null in both groups at every phase.

A switch or augmentation of therapy is required by no less than a third of patients taking antipsychotics, the author concludes on pages 31 to 32, and quetiapine is perceived by psychiatrists as a highly effective and well tolerated antipsychotic with a broad spectrum of action going beyond the official indications; his own closing sentence adds that doctors' ideas about the antiresistant properties of the drug require confirmation in real clinical practice and in randomised trials. The article is sponsored by NovaMedica, and a patient entered the programme only if the treating doctor had already decided on quetiapine.

The authors' head conclusion is that mono- and combination therapy exhibited substantial heterogeneity in their effectiveness for preventing psychiatric hospitalisation, and that hospitalisation, together with hospitalisation of any cause, is the whole of what this publication measures.

The waiver disappeared and the share of newly diagnosed adults given buprenorphine moved from 18.8% to 19.6%, while retention, overdose and death were not measured at all.

After page 12 the report gives no mortality figure at all: not in the results, not in the overview, not in the conclusion, not in the appendices.

Eligibility, not effect size, decides the national arithmetic: 1.03 million people can receive the drug, 6.16 million can receive the care.

The first antipsychotic course in dementia runs to a model-adjusted median of seven months in a system whose guidance is written in weeks.

A system can disseminate a protocol nationwide and still deliver a full course to only about a third of the patients who begin one.

A questionnaire with no items on depersonalisation cannot tell you how common depersonalisation is.

The developer funded the investigation, blinding was never tested, and the registry, filed after the trial had closed, lists two primary outcomes where the paper reports one.

An inert tablet produced a little under half the measured improvement, and the abstract puts adverse events at 44.44 percent in that same control column.

The guideline times every taper to the week and specifies immediate withdrawal when the liver or the blood count says so; for planned stopping of maintenance treatment, sections 1.7 and 1.10 name no threshold in episodes or months of remission and leave the moment inside a required conversation.

The programme counts completions, preceptors and prescribers; its own report measures neither retention in treatment nor overdoses nor deaths, and names retention once, among next year's plans.

The manual is a content base, not a stand-alone intervention: the largest iSupport trial to date found no separation from usual care when carers were left to work through it alone.

One plenary places EMDR as an adjunct rather than a treatment for dissociative identity disorder, another asks when and how to use it, and reading both beats any paragraph that settles the question for you.